Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 10Withdrawn 3Terminated 3Recruiting 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 96INDUSTRY 31NIH 16NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 30Other hematologic neoplasm 26Lymphoid 25Genitourinary 22CNS 19Plasma cell 17Thoracic 15Gastrointestinal 14Head & Neck 7Sarcoma 6Myeloid 6Tumor-Agnostic 5Gynecologic 5Dermatologic 3Other neoplasm 2Endocrine 2Other solid neoplasm 1

Conditions

Somatostatinoma 2Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Neuroendocrine 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Temozolomide 2Capecitabine 2Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × NETWORK × Endocrine × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡